OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
August 06 2024 - 6:00AM
OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage
biopharmaceutical company developing innovative ocular therapies
for the treatment of inflammatory dry eye disease (DED), a
multi-billion-dollar market, and anterior ocular segment diseases
including neuropathic corneal pain (NCP), an ocular condition
associated with pain but without an FDA approved
therapy, announced today the grant of a key European Patent
entitled: “Compositions Comprising Chemerin Analogs and Methods of
Use”. The present disclosure that lists Raj Patil, Chief Scientific
Officer of OKYO Pharma as a joint Inventor, relates to novel OK-101
chemerin analogs for use in treating various diseases and
conditions including but not limited to, ocular inflammatory and
pain conditions, strengthening the Company’s intellectual property
position in this field.
"We are delighted with the issuance of this European patent,
which underscores the innovative nature of our OK-101 chemerin
analogs and their therapeutic potential. This milestone strengthens
our intellectual property portfolio and positions OKYO Pharma for
continued advancement in addressing significant unmet medical
needs," commented Dr. Gary S. Jacob, Ph.D., CEO of OKYO. “The
issuance of this patent further solidifies OKYO Pharma's commitment
to advancing novel therapies that aim to improve outcomes for
patients suffering from ocular pain and inflammation. The company
continues to explore strategic partnerships and collaborations to
accelerate the development and commercialization of its pipeline
candidates.”
About OK-101OK-101 is a lipid conjugated
chemerin peptide agonist of the ChemR23 G-protein coupled receptor
which is typically found on immune cells of the eye responsible for
the inflammatory response. OK-101 was developed using a
membrane-anchored-peptide technology to produce a novel long-acting
drug candidate for treating dry eye disease. OK-101 has been shown
to produce anti-inflammatory and pain-reducing efficacy signals in
mouse models of dry eye disease and corneal neuropathic pain (NCP),
respectively, and is designed to combat washout through the
inclusion of the lipid anchor built into the drug molecule to
enhance the residence time of OK-101 within the ocular environment.
OK-101 recently showed statistical significance in multiple
endpoints in a recently completed Phase 2, multi-center,
double-blind, placebo-controlled trial of OK-101 to treat DED.
About OKYOOKYO Pharma Limited (NASDAQ: OKYO) is
a clinical stage biopharmaceutical company developing innovative
therapies for the treatment of DED and NCP, with ordinary shares
listed for trading on the NASDAQ Capital Market. OKYO is focused on
the discovery and development of novel molecules to treat
inflammatory DED and ocular pain. In addition to the recently
completed Phase 2 DED trial, OKYO also has plans underway for the
opening of a Phase 2 trial for OK-101 to treat NCP in patients with
this debilitating condition. For further information, please
visit www.okyopharma.com.
Forward-Looking StatementsCertain statements
made in this announcement are forward-looking statements. These
forward-looking statements are not historical facts but rather are
based on the Company’s current expectations, estimates, and
projections about its industry, its beliefs, and assumptions. Words
such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’
‘seeks,’ ‘estimates,’ and similar expressions are intended to
identify forward-looking statements. These statements are not
guarantees of future performance and are subject to known and
unknown risks, uncertainties, and other factors, some of which are
beyond the Company’s control, are difficult to predict, and could
cause actual results to differ materially from those expressed or
forecasted in the forward-looking statements. These and additional
risks and uncertainties are described more fully in the company’s
filings with the SEC, including those factors identified as “Risk
Factors” in our most recent Annual Report on Form 20-F, for the
fiscal year ended March 31, 2023. The Company cautions
security holders and prospective security holders not to place
undue reliance on these forward-looking statements, which reflect
the view of the Company only as of the date of this announcement.
The forward-looking statements made in this announcement relate
only to events as of the date on which the statements are made. The
Company will not undertake any obligation to release publicly any
revisions or updates to these forward-looking statements to reflect
events, circumstances, or unanticipated events occurring after the
date of this announcement except as required by law or by any
appropriate regulatory authority.
Enquiries:
OKYO Pharma Limited |
Gary S. Jacob, Chief Executive Officer |
917-497-7560 |
Business Development
&Investor Relations |
Paul Spencer |
+44 (0)20 7495 2379 |
OKYO Pharma (NASDAQ:OKYO)
Historical Stock Chart
From Aug 2024 to Sep 2024
OKYO Pharma (NASDAQ:OKYO)
Historical Stock Chart
From Sep 2023 to Sep 2024